Liang Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Liang Sun has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Citlali Gutierrez
Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Matthews Avenue, Urbana, IL 61801, USA
2 shared publications - Kai Gui
Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Matthews Avenue, Urbana, IL 61801, USA
2 shared publications - Karna Terpstra
Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Matthews Avenue, Urbana, IL 61801, USA
2 shared publications - Liviu M. Mirica
University of Illinois Urbana−Champaign 600 S. Mathews Avenue
2 shared publications - Yiran Huang
Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Matthews Avenue, Urbana, IL 61801, USA
2 shared publications
Latest Publications
- Open Access
N-Alkylamino Stilbene Compounds as Amyloid β Inhibitors for Alzheimer’s Disease Research
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that debilitates an overwhelming number of people in the aging population worldwide. The aggregated forms of the amyloid beta (Aβ) peptide play an important role in the onset of AD. Small molecules that can bind to Aβ are useful for in vitro assays, in vivo imaging, and in therapeutic research. Herein, a series of compounds that can target Aβ aggregates and inhibit their formation were developed. The interaction of several compounds with the Aβ peptide was found to modulate the formation of aggregates. These N-alkylamino stilbene compounds offer selectivity toward Aβ species against other in situ proteins and have potential for aiding the development of soluble Aβ aggregate selective AD probes.
Open AccessN-Alkylamino Stilbene Compounds as Amyloid β Inhibitors for Alzheimer’s Disease Research
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that debilitates an overwhelming number of people in the aging population worldwide. The aggregated forms of the amyloid beta (Aβ) peptide play an important role in the onset of AD. Small molecules that can bind to Aβ are useful for in vitro assays, in vivo imaging, and in therapeutic research. Herein, a series of compounds that can target Aβ aggregates and inhibit their formation were developed. The interaction of several compounds with the Aβ peptide was found to modulate the formation of aggregates. These N-alkylamino stilbene compounds offer selectivity toward Aβ species against other in situ proteins and have potential for aiding the development of soluble Aβ aggregate selective AD probes.
- Open Access
- 23 April 2025
- Published by MDPI AG in Preprints.org
N-Alkylamino Stilbene Compounds as Amyloid β Inhibitors for Alzheimer's Disease Research
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that debilitates an overwhelming number of people in the aging population worldwide. The aggregated forms of the beta-amyloid (Aβ) peptide play an important role in the onset of AD. Small molecules that can bind to Aβ are useful for in vitro assays, in vivo imaging, and in therapeutic research. Herein, a series of compounds that can target Aβ aggregates and inhibit their formation were developed. The interaction of several compounds with the Aβ peptide was found to modulate the formation of aggregates. These N-alkylamino stilbene compounds offer important Aβ selectivity and have potential for aiding the development of soluble Aβ aggregate selective AD probes.
- 23 April 2025
- Published by MDPI AG in Preprints.org
Open AccessN-Alkylamino Stilbene Compounds as Amyloid β Inhibitors for Alzheimer's Disease Research
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that debilitates an overwhelming number of people in the aging population worldwide. The aggregated forms of the beta-amyloid (Aβ) peptide play an important role in the onset of AD. Small molecules that can bind to Aβ are useful for in vitro assays, in vivo imaging, and in therapeutic research. Herein, a series of compounds that can target Aβ aggregates and inhibit their formation were developed. The interaction of several compounds with the Aβ peptide was found to modulate the formation of aggregates. These N-alkylamino stilbene compounds offer important Aβ selectivity and have potential for aiding the development of soluble Aβ aggregate selective AD probes.